Innovations in superficial bladder cancer treatments. Review

2007 ◽  
Vol 74 (3) ◽  
pp. 133-138 ◽  
Author(s):  
M. Racioppi ◽  
A. Volpe ◽  
R. Falabella ◽  
E. Cappa ◽  
D. D'Agostino ◽  
...  

Bladder cancer treatment is a challenge for both urologists and oncologists. Particularly during these last years many changes have been made in the management of superficial bladder cancer. In the case of superficial bladder cancer, intravesical instillation of chemo/immunotherapeutic agents after transurethral resection is the standard. The treatment goals include: complete removal of the initial tumor, prevention of recurrences and inhibition of disease progression. This work aims at reviewing the new developments in the therapeutic field of superficial bladder cancer. A growing trend involves the use of multimodality treatment to obtain the activation of the host immunity against the tumor, and to enhance the cytotoxic effects of chemotherapeutic agents. The new therapeutic modalities, which are under preclinical and clinical investigations, are showing promising results.

1994 ◽  
Vol 35 (S1) ◽  
pp. S31-S35 ◽  
Author(s):  
Kikuo Okamura ◽  
Tatsuro Murase ◽  
Koji Obata ◽  
Shinichi Ohshima ◽  
Yoshinari Ono ◽  
...  

2007 ◽  
Vol 177 (4S) ◽  
pp. 293-293
Author(s):  
Satoshi Anai ◽  
Atsushi Tomioka ◽  
Yoshihiko Hirao ◽  
Ikumi Sugiyama ◽  
Yasuyuki Sadzuka ◽  
...  

2006 ◽  
Vol 176 (4) ◽  
pp. 1349-1353 ◽  
Author(s):  
Antoine G. van der Heijden ◽  
Paula M.J. Moonen ◽  
Erik B. Cornel ◽  
Henk Vergunst ◽  
Theo M. de Reijke ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-5 ◽  
Author(s):  
Tomonori Kato ◽  
Kazushi Nomura ◽  
Fukuo Kondo ◽  
Masami Wakisaka ◽  
Akira Komiya

The high incidence of tumor recurrence following transurethral resection (TUR) represents a major problem encountered in the management of bladder cancer. This study examined the efficacy of intravesical chemotherapy in superficial bladder cancer. We retrospectively analyzed 90 Japanese cases with low-grade superficial transitional cell carcinoma (stage T1, grades 1 and 2) who were rendered tumor-free by TURBT (TUR of bladder tumor) and who thereafter were treated with or without intravesical chemotherapy. Among them, instillation was terminated in 2 patients due to adverse effects (severe but reversible chemical cystitis). Remaining 88 patients were divided into 2 groups according to therapy: the TURBT-only group(n=46), defined as patients treated with TURBT alone, and the Instillation group(n=42), defined as patients treated with weekly intravesical instillation therapies using epirubicin plus Ara-C. Recurrence-free rate was significantly higher in the Instillation group than in the TURBT-only group (p=0.02, HR = 0.457). The 5-year recurrence-free rate was 58.5% for the Instillation group and 38.6% for the TURBT-only group. Our instillation schedule represents the most intensive regimen among previously reported therapies and resulted in a 54.3% decrease in incidence of tumor recurrence. We believe that the results of this study could provide useful information on management of bladder cancer.


Sign in / Sign up

Export Citation Format

Share Document